dpp-4 inhibitor with glp-1 receptor agonist combination not recommended ada πππππ¬π π©π¨π¬π’ππ’π¨π§ π¨π πππ-π π’π§π‘π’ππ’ππ¨π«π¬ (π.π ., π¬π’πππ π₯π’π©ππ’π§, π¬ππ±ππ π₯π’π©ππ’π§, π₯π’π§ππ π₯π’π©ππ’π§, ππ₯π¨π π₯π’π©ππ’π§, π―π’π₯πππ π₯π’π©ππ’π§) π’π§ ππ‘π ππππ πππ ππππ§πππ«ππ¬ π¨π ADA 2025 guidelines for diabetes
Description
Together, these add up to a lot of extra cheap and tasty extra calories from ultra-processed foods that we love to overeat
GLP-1 RAs demonstrate metabolic efficacy but present diverse adverse events
Conclusions Dipeptidyl peptidase-4 (DPP-4) inhibitors are oral diabetes medications that inhibit the enzyme DPP-4, a ubiquitous enzyme that is expressed on the surface of most cell types and deactivates a variety of other bioactive peptides, including glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)
As previously reviewed, weight reduction can help improve MASLD/MASH significantly
GLP1s are game changers across the map
This dual mechanism appears to produce even greater effects on blood sugar and body weight than GLP-1-only medications
